In vitro evaluation of cationic liposomal delivery of BDNF expressing plasmid DNA in experimental model of Parkinson's disease

Avachat, Charul

doi:10.17760/d20261856

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These nonviral carriers are based on the electrostatic interactions of cationic compounds that spontaneously complex with the BDNF plasmid. Polymer-based vectors exhibit a number of desirable traits, including ease of manufacturing, good safety and stability, low immunogenicity, and simple methods to incorporate target ligands [ 350 , 351 ]. Unfortunately, the transfection efficiency of polymers as gene-delivery vectors is several orders of magnitude lower than that of recombinant viruses.…”

Section: Bdnf-targeting Strategies For Ad Modificationmentioning

confidence: 99%

Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

Gao

Zhang

Sterling

et al. 2022

Transl Neurodegener

234

View full text Add to dashboard Cite

Synaptic abnormalities are a cardinal feature of Alzheimer’s disease (AD) that are known to arise as the disease progresses. A growing body of evidence suggests that pathological alterations to neuronal circuits and synapses may provide a mechanistic link between amyloid β (Aβ) and tau pathology and thus may serve as an obligatory relay of the cognitive impairment in AD. Brain-derived neurotrophic factors (BDNFs) play an important role in maintaining synaptic plasticity in learning and memory. Considering AD as a synaptic disorder, BDNF has attracted increasing attention as a potential diagnostic biomarker and a therapeutical molecule for AD. Although depletion of BDNF has been linked with Aβ accumulation, tau phosphorylation, neuroinflammation and neuronal apoptosis, the exact mechanisms underlying the effect of impaired BDNF signaling on AD are still unknown. Here, we present an overview of how BDNF genomic structure is connected to factors that regulate BDNF signaling. We then discuss the role of BDNF in AD and the potential of BDNF-targeting therapeutics for AD.

show abstract

Section: Bdnf-targeting Strategies For Ad Modificationmentioning

confidence: 99%